Opinion|Videos|March 28, 2025
Health Care System Integration
Experts discuss the role of continuous glucose monitoring (CGM)-derived metrics, particularly glucose management indicator (GMI), in the new Healthcare Effectiveness Data and Information Set (HEDIS) diabetes care measures and ACO quality targets, and how CGM-specific metrics are being incorporated into the National Committee for Quality Assurance (NCQA)’s quality measures and the implications for health plans.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What role do CGM-derived metrics, particularly GMI, play in the new HEDIS diabetes care measures and ACO quality targets?
How are CGM-specific metrics being incorporated into NCQA’S quality measures, and what implications does this have for health plans?
Advertisement
Related to this article
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.
Mark Belkin, MD, explains why HFpEF goes undiagnosed, how MRA evidence should guide therapy, and what's next for AI-driven care.
Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.
Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on the Cover of the October issue of Evidence-Based Oncology.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
4
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
5